Giving β-blockers to patients with heart failure or a recent myocardial infarction can lower the risk of major adverse cardiovascular events (MACE) and all-cause mortality within 30 days after noncardiac surgery, according to a large Danish retrospective cohort study (Andersson C et al. JAMA Intern Med. doi:10.1001/jamainternmed.2013.11349 [published online November 18, 2013]). But among patients with stable heart disease, there was no association between β-blocker use and MACE or mortality.
Slomski A. β-Blockers Before Noncardiac Surgery Help Only Some Heart Patients. JAMA. 2013;310(24):2605. doi:10.1001/jama.2013.284785